Techsomed Launches Ultrasound-Based Software Suite for Liver Tumor Ablation Therapy
Featuring the previously FDA-cleared BioTraceIO Vision and BioTraceIO Precision modalities, the BioTrace software suite combines real-time ultrasound guidance and advanced AI technology to help bolster outcomes with liver tumor ablation therapy.
For patients with liver tumors, the emergence of a new software suite may enhance the accuracy and efficiency of ultrasound-guided treatment.
The recently launched BioTrace software suite includes BioTraceIO Vision and BioTraceIO Precision, two modalities that were previously cleared by the Food and Drug Administration (FDA) for use in liver tumor ablation, according to Techsomed, the manufacturer of the modalities.
For interventional radiologists, BioTraceIO Vision may enhance pre-op planning of liver tumor ablation procedures and BioTraceIO Precision provides assessments for post-ablation tissue damage based on real-time ultrasound images, according to Techsomed, the developer of both software modalities. (Image courtesy of Techsomed.)
For the assessment and treatment planning of patients with liver tumors, TechsoMed said interventional radiologists may utilize the artificial intelligence (AI)-powered BioTraceIO Vision for targeted ablation therapy based on ultrasound guidance. In order to access predictive insights on post-ablation tissue damage, clinicians may employ BioTraceIO Precision to get assessments based on real-time ultrasound imaging, according to Techsomed.
“We are thrilled to bring our BioTrace software suite, including both BioTraceIO Vision and BioTraceIO Precision, for patient care in the United States. … We look forward to partnering with leading medical institutions to revolutionize the standard of care in ablation therapy, offering patients the benefits of enhanced treatment precision aimed to improve outcomes,” noted Yossi Abu, the CEO of Techsomed.
Recent Videos
Related Content
Emerging AI Software for Prostate MRI Offers 95 Percent Sensitivity for csPCa
February 28th 2025Article
In a multicenter study involving over 1,000 patients, a deep learning software offered comparable sensitivity and specificity for Gleason grade group > 2 tumors in comparison to radiologist interpretation.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Podcast
Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Can CT-Based AI Help Predict Renal Function Decline After Radioligand Therapy for mCRPC?
February 25th 2025Article
In patients who had at least four cycles of 177Lu-PSMA-I&T for mCRPC, new research shows that a 10 percent or greater decrease in total kidney volume on CT at six months has a 90 percent AUC for predicting estimated glomerular filtration rates (eGFRs) of 30 percent or greater at one year.
